Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study: Crohn's drug shows promise for complete remission

NCT ID NCT05192863

First seen Nov 15, 2025 · Last updated May 24, 2026 · Updated 29 times

Summary

This study looked at whether the drug vedolizumab can help adults with moderate to severe Crohn's disease achieve complete remission—meaning fewer symptoms and less bowel inflammation—after 12 months of treatment. Researchers followed 72 participants in Canada, Italy, and Israel who started vedolizumab as part of their regular care. The goal was to see if the drug could reduce both symptoms and signs of inflammation measured by ultrasound and lab tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • A.O.U. Federico II

    Naples, 80131, Italy

  • ASST Fatebenefratelli Sacco

    Milan, 20157, Italy

  • Fondazione Ca' Granda Ospedale Maggiore Policlinico

    Milan, 20122, Italy

  • Hadassah Medical Center

    Jerusalem, 9112001, Israel

  • Ospedale ASST Rhodense

    Rho, Milano, 20017, Italy

  • Ospedale San Raffaele

    Milan, 20132, Italy

  • Rabin Medical Center

    Petah Tikva, 4941492, Israel

  • Sheba Medical Center

    Ramat Gan, 5262000, Israel

  • University of Calgary

    Calgary, Alberta, T2N 4N1, Canada

  • University of Saskatchewan

    Saskatoon, Saskatchewan, S7N 0W8, Canada

Conditions

Explore the condition pages connected to this study.